Oruka Therapeutics, Inc. (ORKA), Friday announced the preclinical data for ORKA-002, a novel extended half-life monoclonal antibody targeting IL-17A/F.
The findings, presented at the 2025 American Academy of Dermatology Annual Meeting, revealed that half-life in non-human primates of more than 30 days, is over three times longer than bimekizumab and expected to support a dose interval of two to three times per year.
The company further expects ORKA-002 to offer an even better product profile to people with psoriasis, psoriatic arthritis, and additional indications.
Oruka added that the first subject dosed with ORKA-002 is expected in the third quarter of 2025.
Currently, Oruka's stock is trading at $10.05, down 0.20 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.